Brivaracetam News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Brivaracetam. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Brivaracetam Today - Breaking & Trending Today
Monday, Addex Therapeutics (NASDAQ:ADXN) released top-line data from a Phase 2 epilepsy study evaluating adjunctive ADX71149 (JNJ-40411813) administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam. The company is collaborating with Johnson & Johnson’s (NYSE:JNJ) Janssen Pharmaceuticals Inc. The Phase 2 study did not achieve statistical significance for the primary endpoint of time for patients to reach baseline seizure count when ADX71149 was ....
Epilepsy Drugs Market is projected to reach US$ 10.3 Billion by 2027. Global Forecast, Impact of COVID-19, Industry Trends, by Drugs Category, Country, Growth, Opportunity Company Analysis. ....
Zydus Cadila has received tentative approval from the US Food and Drug Administration (USFDA) to market Brivaracetam tablets, in the strengths of 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, Cadila Healthcare said in a regulatory filing. ....
Read more about Zydus Cadila receives USFDA tentative approval for Brivaracetam Tablets on Business Standard. The drug will be manufactured at the group s formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 319 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04. ....
Alkem Labs launches affordable anti-epileptic drug in India Alkem Labs launches affordable anti-epileptic drug in India 15 March 2021 | News Source credit: Shutterstock Mumbai based Alkem Laboratories has announced the launch of Brivasure, an affordable anti-epileptic drug for the treatment of epilepsy in India. Brivasure, Alkem’s anti-epileptic drug (AED) is a generic version of the parent molecule. Alkem has launched the drug in the market at price, Brivasure 25mg Rs 79.50/strip, Brivasure 50mg 148.50/strip, Brivasure 75mg 230/strip, Brivasure 100mg 295/strip, post patent expiry of innovator product, of Brivaracetam as on February 21, 2021. The drug has been approved by the Drugs Controller General of India (DCGI) in the adjunctive management of partial onset seizure with or without secondary generalisation. The drug has exhibited faster onset of action, efficacy with favourable safety profile. ....